Evidence map›Paper›PMID 34976856›Full record

ArticleFrontiers in cellular and infection microbiology2021

High-Throughput Screening and Identification of Human Adenovirus Type 5 Inhibitors.

Xiaojing Wen, Li Zhang, Shan Zhao, Qiang Liu, Wenyi Guan, Jiajing Wu, Qiwei Zhang, Hongling Wen, Weijin Huang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Journal of traditional and complementary medicine · 2026
    Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Xiaojing WenDivision of Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and World Health Organization (WHO) Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.
Li ZhangDivision of Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and World Health Organization (WHO) Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.
Shan ZhaoGuangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Qiang LiuDivision of Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and World Health Organization (WHO) Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.
Wenyi GuanGuangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Jiajing WuDivision of Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and World Health Organization (WHO) Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.
Qiwei ZhangGuangdong Provincial Key Laboratory of Tropical Disease Research, School of Public Health, Southern Medical University, Guangzhou, China.
Hongling WenDepartment of Microbiological Laboratory Technology, School of Public Health, Cheeloo College of Medicine, Key Laboratory for the Prevention and Control of Infectious Diseases, Shandong University, Jinan, China.
Weijin HuangDivision of Human Immunodeficiency Virus (HIV)/Acquired Immune Deficiency Syndrome (AIDS) and Sex-Transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC) and World Health Organization (WHO) Collaborating Center for Standardization and Evaluation of Biologicals, Beijing, China.
National Institutes for Food and Drug Control · CNSouthern Medical University · CNJinan University · CNShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human adenovirus infections can develop into diffuse multi-organ diseases in young children and immunocompromised patients, and severe cases can lead to death. However, there are no approved antiviral drugs available to treat adenovirus diseases. In this study, a chemiluminescence-based, high-throughput screening (HTS) assay was developed and applied to screen human adenovirus 5(HAdV5)inhibitors from 1,813 approved drug library and 556 traditional Chinese medicine-sourced small-molecule compounds. We identified three compounds with

Indexed as

Adenoviruses, HumanAdenovirus Infections, HumanAdenoviridaeAnimalsAntiviral AgentsChild, PreschoolHigh-Throughput Screening AssaysHumansMiceVirus ReplicationAntiviral Agentsadenoviruscardamomindrughigh-throughput screeninginhibitor

Identifiers

PMID34976856
PMCPMC8718806
OpenAlexW4200000501

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.